Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study

European Journal of Cancer

Volumn 30, Issue 7, 1994, Pages 911-914

  Tumolo, S ^e   Ramanath Rao, B ^b   van der Burg, M E ^a   Guastalla, J P ^c   Renard, J ^d   Vermorken, J B ^b  

^a Integraal Kankercentrum Rotterdam   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CENTRE LÉON BÉRARD   (France)

^d EORTC DATA CENTER   (Belgium)

^e NONE

Author keywords

epithelial ovarian cancer; flutamide; phase II

Indexed keywords

FLUTAMIDE; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FLUTAMIDE; HUMAN; MIDDLE AGE; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0028146163     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(94)90112-0     Document Type: Article

References (31)

1. Cancer Statistics 1991
2. Common epithelial cancer of the ovary (first of two parts)
3. Common epithelial cancer of the ovary (second of two parts)
4. Androgen receptor predominance in human ovarian carcinoma
5. Correlation of aromatase activity and steroid receptors in human ovarian carcinoma
6. Gonadotropic hormone binding to human ovarian tumors
7. LH (hCG) receptor in benign and malignant tumors of human ovary
8. GnRh-binding sites in human epithelial ovarian carcinoma
9. Controlled environments and cancer incidence in the domestic fowl
10. Ovarian cancer and its response to endocrine treatment
11. New drugs and experimental approaches in ovarian cancer treatment.
12. High-dose medroxyprogesterone acetate in advanced ovarian cancer
13. The role of Tamoxifen as second line therapy in advanced ovarian cancer evaluated for receptor status and tumor grade
14. Tamoxifen therapy in recurrent epithelial ovarian carcinoma
15. Androgen therapy in the treatment of refractory epithelial ovarian cancer
16. Phase II study of aminogluthetimide in advanced ovarian cancer
17. Diethylstilbestrol as a chemotherapeutic agent for ovarian cancer
18. Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer
19. Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer
20. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer
21. A Phase II Trial of Leuprolide Acetate in Patients with Advanced Epithelial Ovarian Carcinoma
22. Chemotherapy and hormonal treatment in ovarian cancer: experiences of EORTC Gynecological Cancer Cooperative Group
23. Ovarian and adrenal steroid production in the postmenopausal woman
24. The hormonal activity of the post-menopausal ovary
25. Experience with Flutamide in patients with advanced prostatic cancer without prior endocrine therapy
26. Combination therapy with flutamide and castration (LHRH agonist or orchiectmyo) in advanced prostate cancer: a marked improvement in response and survival
27. A phase II clinical trial of Flutamide in the treatment of advanced breast cancer
28. The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Oncology Group study
29. Ovarian cancer (review): etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy
30. Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma
31. Clinical significance of estrogen and progestin receptors in ovarian cancer